Pharma News
Agreement to produce similar biotherapeutic product in Turkey
On 22 October 2021, an important agreement was signed between Nobel Pharmaceuticals and the IBG-OzBio partnership for the manufacturing of a similar biotherapeutic product in Turkey. This hopes to be a springboard for further collaborations and medicinal product development in the country.
Collaborations to commercialize oncology biosimilars
New collaborations to commercialize oncology biosimilars have been announced between Sandoz and Bio-Thera Solutions, and between Innovent Biologics and Ascentage Pharma.
Licensing agreements signed for ustekinumab biosimilars
Bio-Thera Solutions have signed an exclusive commercialization and licensing agreement with Hikma Pharmaceuticals for the ustekinumab (Stelara) biosimilar BAT2206, similar to an agreement reached between Meiji Seika Pharma, Dong-A ST and Intas Pharmaceuticals.
Oncogen–BrightGene partnership
In June 2021, Malaysian oncology generics company, Oncogen, and China’s BrightGene Bio-Medical Technology announced that they are partnering to develop, manufacture, market and distribute generic drug products for the US market.
Menagen–CKD Middle Eastern partnership
Omani company, Menagen Pharmaceutical Industries and Korean company, Chong Kun Dang Pharmaceutical Corp (CKD), have formed a strategic partnership to provide biosimilars to countries in the Middle East.
Teva signs deal with Bioeq for ranibizumab biosimilar FYB201
Israeli generics giant Teva Pharmaceutical Industries (Teva) and Swiss biotechnology company Bioeq AG announced on 28 June 2021 that they had entered into a strategic partnership for the exclusive commercialization of Bioeq’s candidate ranibizumab biosimilar (FYB201) in Europe, Canada, Israel and New Zealand.
Organon launches as new global women’s health company and appoints leaders in Latin America
Organon celebrated its launch as a global women’s health company on 3 June 2021 with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange.
Prestige-Cytiva partnership and new Korean R & D facility
Singapore-based Prestige BioPharma, which specializes in the development of antibody therapeutics, is to build a new research and development (R & D) facility in the Republic of Korea and has entered a strategic partnership with Cytiva.
Theramex to market Prolia biosimilar in Europe and Australia
UK-based pharmaceutical company Theramex UK Ltd, which focuses on women’s health, has announced an agreement with India’s Enzene Biosciences Limited for the registration and commercialisation of a Prolia (denosumab) biosimilar in Europe and Australia.
AbbVie antitrust investigation and Sandoz biosimilar delay
In May 2021, following the release of a report, it was announced that AbbVie is likely to be subject to an antitrust investigation due to claims it has delayed market entry of biosimilars of Humira (adalimumab). Alvotech also raised a complaint against AbbVie after being sued over their Humira biosimilar application. In addition, the US Supreme Court denied Sandoz the ability to release its Enbrel (etanercept) biosimilar.
